Brainstorm Cell Therapeutics (BCLI)
(Delayed Data from NSDQ)
$0.46 USD
-0.01 (-2.36%)
Updated May 10, 2024 04:00 PM ET
After-Market: $0.45 -0.01 (-1.32%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMDetailed Estimates
EPS Estimates
Exp Earnings Date | 5/20/24 |
---|---|
Current Quarter | -0.07 |
EPS Last Quarter | -0.11 |
Last EPS Surprise | 26.67% |
ABR | 3.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -0.28 |
Next Year | -0.24 |
EPS (TTM) | -0.52 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.07 | -0.07 | -0.28 | -0.24 |
# of Estimates | 1 | 1 | 1 | 1 |
Most Recent Consensus | -0.07 | -0.07 | -0.28 | -0.24 |
High Estimate | -0.07 | -0.07 | -0.28 | -0.24 |
Low Estimate | -0.07 | -0.07 | -0.28 | -0.24 |
Year ago EPS | -0.14 | -0.13 | -0.51 | -0.28 |
Year over Year Growth Est. | 50.00% | 46.15% | 45.10% | 14.29% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 1 | 1 |
Up Last 60 Days | 0 | 0 | 1 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.07 | -0.07 | -0.28 | -0.24 |
7 Days Ago | -0.07 | -0.07 | -0.28 | -0.24 |
30 Days Ago | NA | NA | -0.47 | -0.47 |
60 Days Ago | NA | NA | -0.47 | -0.47 |
90 Days Ago | NA | NA | -0.47 | -0.47 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.07 | -0.07 | -0.28 | -0.24 |
Zacks Consensus Estimate | -0.07 | -0.07 | -0.28 | -0.24 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.11 | -0.14 | -0.13 | -0.14 | NA |
Estimate | -0.15 | -0.14 | -0.15 | -0.16 | NA |
Difference | 0.04 | 0.00 | 0.02 | 0.02 | 0.02 |
Surprise | 26.67% | 0.00% | -80.00% | 12.50% | -10.21% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more